JD Health International Inc. disclosed on 25 June 2026 that it repurchased an additional 0.50 million ordinary shares on the Hong Kong Stock Exchange, paying between HKD 32.64 and HKD 33.68 per share for a total outlay of HKD 16.53 million. The shares are earmarked for cancellation.

The latest transaction leaves the company’s issued share capital unchanged at 3.211 billion shares, as the repurchased shares have not yet been cancelled.

Since the current mandate was approved on 20 June 2025, JD Health has bought back 20.44 million shares—equal to 0.64 % of the share count on the mandate date. The company is authorised to repurchase up to 320.01 million shares, meaning 299.57 million shares (93.60 % of the mandate) remain available.

Under HKEX Rule 10.06(3)(a), JD Health is restricted from issuing new shares or transferring treasury shares until 25 July 2026.